| Dr Blanca Guadalupe Cervantes, MD | |
|
1800 N Bush St, Suite 104, Santa Ana, CA 92706-2852 | |
| (714) 294-6705 | |
| (714) 884-4149 |
| Full Name | Dr Blanca Guadalupe Cervantes |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 1800 N Bush St, Santa Ana, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003134263 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | A119138 (California) | Primary |
| Entity Name | Depression Remedy Orange County Tms |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629767629 PECOS PAC ID: 3072974401 Enrollment ID: O20230802001085 |
News Archive
Researchers from a consortium of hospitals including Children's Hospital of Philadelphia (CHOP) have identified factors that make children with diabetic ketoacidosis more likely to experience acute kidney injury.
Despite the striking aromatic differences between coffee, peppermint, and pine, a new mapping of the nose's neural circuitry suggests a haphazard patchwork where the receptors for such disparate scents are as likely as not to be neighbors.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.
Incidence of cervical cancer in young women is set to decline 75 percent by 2040 with deaths close to eradicated, however older women will face greater risk according to research led by Queen Mary University of London, published today in The Lancet Public Health.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Blanca Guadalupe Cervantes, MD 1800 N Bush St, Suite 104, Santa Ana, CA 92706-2852 Ph: (714) 294-6705 | Dr Blanca Guadalupe Cervantes, MD 1800 N Bush St, Suite 104, Santa Ana, CA 92706-2852 Ph: (714) 294-6705 |
News Archive
Researchers from a consortium of hospitals including Children's Hospital of Philadelphia (CHOP) have identified factors that make children with diabetic ketoacidosis more likely to experience acute kidney injury.
Despite the striking aromatic differences between coffee, peppermint, and pine, a new mapping of the nose's neural circuitry suggests a haphazard patchwork where the receptors for such disparate scents are as likely as not to be neighbors.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.
Incidence of cervical cancer in young women is set to decline 75 percent by 2040 with deaths close to eradicated, however older women will face greater risk according to research led by Queen Mary University of London, published today in The Lancet Public Health.
› Verified 7 days ago
Dr. Baljeet Khurana, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2220 E Fruit St, Suite 216, Santa Ana, CA 92701 Phone: 714-626-0085 | |
Elzbieta Maria Sliwa-luce, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 405 W 5th St Ste 212, Santa Ana, CA 92701 Phone: 714-834-2125 | |
Mr. Kevin Chunkai Jou, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 505 N Tustin Ave Ste 150, Santa Ana, CA 92705 Phone: 714-274-7577 | |
Dr. Lawrence Douglas Sporty, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: Lawrence D. Sporty, M.d. 2021 East Fourth Street, Suite 118, Santa Ana, CA 92705 Phone: 714-285-0870 | |
Reda Gamal, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1125 E 17th St Suite W-238, Santa Ana, CA 92701 Phone: 714-245-0353 Fax: 714-569-0492 | |
Dr. Weiming David Chu, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 520 N Main St Ste 220, Santa Ana, CA 92701 Phone: 714-352-5800 Fax: 714-352-5801 |